Trigon and mBank S.A. successfully executed a 63 million PLN Accelerated Bookbuilding transaction for Bioceltix S.A., facilitating funds for the construction of a major veterinary medicine production facility.
Target Company Overview
Bioceltix S.A. is a publicly traded company on the Warsaw Stock Exchange, focused on developing innovative veterinary medications based on stem cell technology. The company has established itself as a leader in the biopharmaceutical sector, aiming to create advanced treatments that enhance the health and well-being of animals.
With the increasing demand for effective veterinary solutions, Bioceltix's commitment to research and development positions it favorably within the life sciences industry, making its innovations crucial for addressing market needs.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in Poland
The biopharmaceutical industry in Poland has shown remarkable growth in recent years, driven by advancements in medical research and increased investment in health technologie
Similar Deals
Polmed S.A. → Kliniki Neuroradiochirurgii
2024
Trigon
invested in
Bioceltix S.A.
in 2025
in a Other deal
Disclosed details
Transaction Size: $16M